Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarterly period ended September 30, 2002. The registrant is a foreign private issuer based in South Melbourne, Australia, operating in the biotechnology sector. The report was signed on November 18, 2002.
Key Financial Metrics
| Metric | Value (AUD '000) |
|---|---|
| Receipts from Customers | 368 |
| Net Operating Cash Flows | (1,211) |
| Net Investing Cash Flows | (2) |
| Net Financing Cash Flows | 37 |
| Net Decrease in Cash | (1,176) |
| Cash at End of Quarter | 2,409 |
| Staff Costs | (232) |
| Research and Development Costs | (503) |
| Payments to Directors and Associates | 312 |
The filing does not provide a clear value for revenue recognition under accrual accounting, net profit/loss, or total debt, as the report focuses exclusively on cash flow activities.
Material Changes and Cash Flow Analysis
- Operating Burn: The company generated a net operating cash outflow of $1,211,000. Significant cash outflows were driven by research and development ($503,000) and other working capital items ($867,000).
- Financing Activity: The company raised $37,000 through the issue of shares or options, partially offsetting the operating deficit.
- Liquidity Position: Cash reserves decreased from $3,585,000 at the beginning of the quarter to $2,409,000 at the end. This includes $2,000,000 held in deposits at call.
- Related Party Transactions: Total payments to directors, associates, and related entities amounted to $312,000, with $248,000 specifically attributed to related entities.
Guidance, Risks, and Contingencies
The filing text does not provide specific forward-looking guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies beyond the standard compliance statements. The report notes that no non-cash financing or investing activities occurred during the period. There were no acquisitions or disposals of business entities reported.
Investor Verification Checklist
- Verify the nature of the $867,000 classified as "other working capital" payments, as this is the largest single cash outflow.
- Confirm the details of the $37,000 share issuance, including the number of shares issued and the price per share.
- Review the breakdown of the $312,000 paid to directors and related entities to assess potential conflicts of interest or compensation structures.
- Assess the runway of the remaining $2,409,000 cash balance given the quarterly burn rate of approximately $1.2 million.